Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Kirk J. Rowley"'
Autor:
Yadunanda Budigi, Eugenia Z Ong, Luke N Robinson, Li Ching Ong, Kirk J Rowley, Alexander Winnett, Hwee Cheng Tan, Sven Hobbie, Zachary Shriver, Gregory J Babcock, Sylvie Alonso, Eng Eong Ooi
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 2, p e0006209 (2018)
Dengue virus (DENV) infection imposes enormous health and economic burden worldwide with no approved treatment. Several small molecules, including lovastatin, celgosivir, balapiravir and chloroquine have been tested for potential anti-dengue activity
Externí odkaz:
https://doaj.org/article/da1bb4e2da1349ec965886f70c180beb
Autor:
Trevor J Morin, Teresa J Broering, Brett A Leav, Barbra M Blair, Kirk J Rowley, Elisabeth N Boucher, Yang Wang, Peter S Cheslock, Michael Knauber, David B Olsen, Steve W Ludmerer, Gyongyi Szabo, Robert W Finberg, Robert H Purcell, Robert E Lanford, Donna M Ambrosino, Deborah C Molrine, Gregory J Babcock
Publikováno v:
PLoS Pathogens, Vol 8, Iss 8, p e1002895 (2012)
Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of limi
Externí odkaz:
https://doaj.org/article/8744314b7609471e91dbe560c056d0b8
Autor:
Tyree Koch, David Cain, Chong Wai Liew, Hamid Tissire, James R. Myette, Jianzhu Chen, Zachary Shriver, Gregory J. Babcock, Yee Hwa Wong, Julien Lescar, Sylvie Alonso, Rama Sanjay Kirloskar, Vivian Vasconcelos Costa, Kuan Rong Chan, Eng Eong Ooi, Luke Robinson, Kirk J. Rowley, Boopathy Ramakrishnan, Li Ching Ong, Viswanathan Sasisekharan, Ram Sasisekharan, Hwee Cheng Tan, Karthik Viswanathan, Kannan Tharakaraman
Publikováno v:
PMC
Dengue is the most common vector-borne viral disease, causing nearly 400 million infections yearly. Currently there are no approved therapies. Antibody epitopes that elicit weak humoral responses may not be accessible by conventional B cell panning m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78b1083c201c181fa81b765f4042d15a
https://doi.org/10.1016/j.cell.2015.06.057
https://doi.org/10.1016/j.cell.2015.06.057
Autor:
Zachary Shriver, Eng Eong Ooi, Alexander Winnett, Li Ching Ong, Kirk J. Rowley, Luke Robinson, Hwee Cheng Tan, Sylvie Alonso, Sven N. Hobbie, Eugenia Z. Ong, Yadunanda Budigi, Gregory J. Babcock
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 12, Iss 2, p e0006209 (2018)
PLoS Neglected Tropical Diseases, Vol 12, Iss 2, p e0006209 (2018)
Dengue virus (DENV) infection imposes enormous health and economic burden worldwide with no approved treatment. Several small molecules, including lovastatin, celgosivir, balapiravir and chloroquine have been tested for potential anti-dengue activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91037a67f5f7206bd11c522dc2d8b868
https://pubmed.ncbi.nlm.nih.gov/29425203
https://pubmed.ncbi.nlm.nih.gov/29425203
Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates
Autor:
Hwee Cheng Tan, Zachary Shriver, Kirk J. Rowley, Gregory J. Babcock, Alexander Winnett, Luke Robinson, Sven Hobbie, Eng Eong Ooi, Eugenia Z. Ong, Yadunanda Budigi
Publikováno v:
Antiviral research. 144
Despite useful in vivo activity, no therapeutic against dengue virus (DENV) has demonstrated efficacy in clinical trials. Herein, we explored dosing and virological endpoints to guide the design of human trials of VIS513, a pan-serotype anti-DENV IgG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd492d371db8a29da71c6f47280420dc
https://pubmed.ncbi.nlm.nih.gov/28529000
https://pubmed.ncbi.nlm.nih.gov/28529000
Autor:
William D. Thomas, Brett Leav, Yang Wang, Susan Sloan, Kirk J. Rowley, Peter S. Cheslock, Leila M. Sevigny, Kerry A. Garrity, Brian J. Booth, Gregory J. Babcock
Publikováno v:
Infection and Immunity. 81:3992-4000
Diphtheria antitoxin (DAT) has been the cornerstone of the treatment of Corynebacterium diphtheriae infection for more than 100 years. Although the global incidence of diphtheria has declined steadily over the last quarter of the 20th century, the di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeddc7ee9bff23c28eeabf8c5371d87b
https://doi.org/10.1128/iai.00462-13
https://doi.org/10.1128/iai.00462-13
Autor:
Gregory J. Babcock, Brian J. Booth, Yang Wang, Susan Sloan, Kirk J. Rowley, Donna M. Ambrosino
Publikováno v:
Antiviral Research. 91:187-194
Replacement of polyclonal anti-rabies immunoglobulin (RIG) used in rabies post-exposure prophylaxis (PEP) with a monoclonal antibody will eliminate cost and availability constraints that currently exist using RIG in the developing world. The human mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da74ca0de77390aca69a48af4cf792ef
https://doi.org/10.1016/j.antiviral.2011.06.002
https://doi.org/10.1016/j.antiviral.2011.06.002
Autor:
Cathleen A. Hanlon, Robert Mandell, Kirk J. Rowley, Josh Self, Gregory J. Babcock, Michael Niezgoda, Susan Sloan, William D. Thomas, Donna M. Ambrosino, Jesse D. Blanton, William C. Weldon, Charles E. Rupprecht
Publikováno v:
Vaccine. 25:2800-2810
Rabies is a zoonosis that results in millions of human exposures worldwide each year. Human monoclonal antibodies (HuMAbs) that neutralize rabies virus may represent one viable strategy for post-exposure prophylaxis in humans, and have many advantage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e24229c2d3b550040f258db692334a
https://doi.org/10.1016/j.vaccine.2006.12.031
https://doi.org/10.1016/j.vaccine.2006.12.031
Autor:
Deborah C. Molrine, Phillip D. Zamore, Yang Wang, Kirk J. Rowley, Zhiping Weng, Donna M. Ambrosino, Sowmya Iyer, Heidi L. Smith, Brian G. Pierce, Gregory J. Babcock
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 6, p e100325 (2014)
PLoS ONE, Vol 9, Iss 6, p e100325 (2014)
Chronic hepatitis C virus (HCV) infection is the most common cause of end-stage liver disease, often leading to liver transplantation, in which case circulating virions typically infect the transplanted liver within hours and viral concentrations can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2796b71eeba7babcb2a92abafbfde6b7
https://doi.org/10.1371/journal.pone.0100325
https://doi.org/10.1371/journal.pone.0100325
Autor:
Peter S. Cheslock, Deborah C. Molrine, Kirk J. Rowley, Trevor J. Morin, Robert E. Lanford, David B. Olsen, Gyongyi Szabo, Elisabeth N. Boucher, Robert H. Purcell, Donna M. Ambrosino, Steve W. Ludmerer, Yang Wang, Teresa J. Broering, Gregory J. Babcock, Brett Leav, Barbara M. Blair, Robert W. Finberg, Michael Knauber
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 8, Iss 8, p e1002895 (2012)
PLoS Pathogens, Vol 8, Iss 8, p e1002895 (2012)
Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of limi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363471029edc57e65e1a0a3279ae7d1d
https://doi.org/10.1371/journal.ppat.1002895
https://doi.org/10.1371/journal.ppat.1002895